MedTrace Logo

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)

NCT03544736 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-22

No results posted yet for this study

Summary

Three parallel cohort, multicenter, open-label, phase I/II clinical trial to analyze the safety and feasibility of PD-1 inhibition with Nivolumab given concomitantly with standard radiotherapy regimens in the treatment of esophageal cancer

Conditions

  • Esophageal Cancer

Interventions

DRUG

Nivolumab

Experimental: Nivolumab

RADIATION

Radiotherapy

Radiotherapy

DRUG

Chemotherapy

Chemotherapy

PROCEDURE

Surgery

Surgery

Sponsors & Collaborators

Principal Investigators

  • Geir O. Hjortland · Oslo University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-26
Primary Completion
2025-12-31
Completion
2040-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03544736 on ClinicalTrials.gov